Drug Combination Details
| General Information of the Combination (ID: C57399) | |||||
|---|---|---|---|---|---|
| Name | Voacamine NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Osteosarcoma
[ICD-11: 2B51]
|
Investigative | [1] | ||
|
Melanoma
[ICD-11: 2C30]
|
Investigative | [1] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | ||
| U-2 OS R1 | CVCL_T429 | Osteosarcoma | Homo sapiens | |||
| Experimental
Result(s) |
The plant alkaloid voacamine induces apoptosis-independent autophagic cell death on both sensitive and multidrug resistant human osteosarcoma cells. | |||||
| Experiment 2 Reporting the Effect of This Combination | [3] | |||||
| Biological
Regulation |
Induction | Autophagic cell death | ||||
| In-vitro Model | U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | ||
| U-2 OS R1 | CVCL_T429 | Osteosarcoma | Homo sapiens | |||
| Experimental
Result(s) |
Voacamine is capable of enhancing the cytotoxic effect of DOX on MDR cells by favouring a lethal autophagic process. | |||||
| Experiment 3 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | SaOS-2 | CVCL_0548 | Osteosarcoma | Homo sapiens | ||
| 30966M | CVCL_WM43 | Melanoma | Homo sapiens | |||
| Experimental
Result(s) |
Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts. | |||||